The Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes  

Oleh:

Kovatchev, Boris ; Tamborlane, William V. ; Cefalu, William T. ; Cobelli, Claudio

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Diabetes Care vol. 39 no. 07 (Jul. 2016), page 1123-1126.
Topik: Continuous Glucose Monitoring; CGM; Artificial Pancreas; AP
Fulltext: D05 v39 n7 p1123 kelik2017.pdf (668.1KB)

Ketersediaan

Perpustakaan FK Nomor Panggil: D05.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

With the increasing availability of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII), the artificial pancreas (AP) (the commonly accepted term for closed-loop control [CLC] of blood glucose [BG] levels in diabetes) has become a hot area in translational research and industrial development. After a prolonged period of inpatient, clinical research center trials using cumbersome systems, the field has progressed rapidly over the past 2 years to long-term, free-living studies running AP algorithms on smartphones. Although it is still not a cure, the AP is the most promising advance in the treatment of diabetes at this time. This issue of Diabetes Care presents today’s AP state of the art, including reports on multinational home-use AP trials, studies in young children, the use of multihormonal approaches to mitigate meal-related hyperglycemia, and discussions of AP study designs and outcome measures. This collection of articles establishes the AP as a new diabetes treatment paradigm—not a single-function CGM or CSII device but an adaptable wearable network encompassing the patient in a digital treatment ecosystem.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali